Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients

Introduction: In peritoneal dialysis (PD) patients, the peritoneal membrane is affected by glucose-based solutions used as peritoneal dialysate fluids. This exposure leads to changes of the membrane which may eventually culminate in fibrosis and method failure. In vitro or animal studies demonstrate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Severin Schricker, Tina Oberacker, Peter Fritz, Markus Ketteler, Mark Dominik Alscher, Moritz Schanz
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	Dermatology RL1-803 Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/bb15b0e468944e739b7005a8fb2d7b12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb15b0e468944e739b7005a8fb2d7b12
record_format	dspace
spelling	oai:doaj.org-article:bb15b0e468944e739b7005a8fb2d7b122021-12-02T12:40:22ZPeritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients1420-40961423-014310.1159/000520894https://doaj.org/article/bb15b0e468944e739b7005a8fb2d7b122021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/520894https://doaj.org/toc/1420-4096https://doaj.org/toc/1423-0143Introduction: In peritoneal dialysis (PD) patients, the peritoneal membrane is affected by glucose-based solutions used as peritoneal dialysate fluids. This exposure leads to changes of the membrane which may eventually culminate in fibrosis and method failure. In vitro or animal studies demonstrated that glucose transporters are upregulated upon exposure to these solutions. Expression studies of glucose transporters in human peritoneum have not been reported yet. Methods: Expression of SGLT-2, GLUT1, and GLUT3 in human peritoneal biopsies was analysed by real-time polymerase chain reaction (qPCR) and Western blot analysis. The localization of these glucose transporters in the peritoneum was evaluated by immunohistochemistry using a Histo-Score. Results: Peritoneal biopsies of patients (healthy controls, uremic, PD and encapsulating peritoneal sclerosis (EPS)) were analyzed. We found evidence of SGLT-2, GLUT1 and GLUT3 expression in the peritoneal membrane. Protein expression of SGLT-2 increases with PD-duration and is significantly enhanced in EPS patients. All transporters were predominantly, but not exclusively, located adjacent to the vessel walls of the peritoneal membrane. Conclusion: Our study showed that SGLT-2, GLUT1 and GLUT3 were regularly expressed in the human peritoneum. SGLT-2 was particularly upregulated in PD patients with EPS, suggesting that this upregulation may be associated with pathological changes in the peritoneal membrane in this syndrome. Since preclinical studies in mice show that SGLT-2 inhibitors or downregulation of SGLT-2 ameliorated pathological changes in the peritoneum, SGLT-2 inhibitors may be potentially promising agents for therapy in PD patients that could reduce glucose absorption and delay functional deterioration of the peritoneal membrane in the long-term.Severin SchrickerTina OberackerPeter FritzMarkus KettelerMark Dominik AlscherMoritz SchanzKarger PublishersarticleDermatologyRL1-803Diseases of the circulatory (Cardiovascular) systemRC666-701Diseases of the genitourinary system. UrologyRC870-923ENKidney & Blood Pressure Research (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803 Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Dermatology RL1-803 Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the genitourinary system. Urology RC870-923 Severin Schricker Tina Oberacker Peter Fritz Markus Ketteler Mark Dominik Alscher Moritz Schanz Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients
description	Introduction: In peritoneal dialysis (PD) patients, the peritoneal membrane is affected by glucose-based solutions used as peritoneal dialysate fluids. This exposure leads to changes of the membrane which may eventually culminate in fibrosis and method failure. In vitro or animal studies demonstrated that glucose transporters are upregulated upon exposure to these solutions. Expression studies of glucose transporters in human peritoneum have not been reported yet. Methods: Expression of SGLT-2, GLUT1, and GLUT3 in human peritoneal biopsies was analysed by real-time polymerase chain reaction (qPCR) and Western blot analysis. The localization of these glucose transporters in the peritoneum was evaluated by immunohistochemistry using a Histo-Score. Results: Peritoneal biopsies of patients (healthy controls, uremic, PD and encapsulating peritoneal sclerosis (EPS)) were analyzed. We found evidence of SGLT-2, GLUT1 and GLUT3 expression in the peritoneal membrane. Protein expression of SGLT-2 increases with PD-duration and is significantly enhanced in EPS patients. All transporters were predominantly, but not exclusively, located adjacent to the vessel walls of the peritoneal membrane. Conclusion: Our study showed that SGLT-2, GLUT1 and GLUT3 were regularly expressed in the human peritoneum. SGLT-2 was particularly upregulated in PD patients with EPS, suggesting that this upregulation may be associated with pathological changes in the peritoneal membrane in this syndrome. Since preclinical studies in mice show that SGLT-2 inhibitors or downregulation of SGLT-2 ameliorated pathological changes in the peritoneum, SGLT-2 inhibitors may be potentially promising agents for therapy in PD patients that could reduce glucose absorption and delay functional deterioration of the peritoneal membrane in the long-term.
format	article
author	Severin Schricker Tina Oberacker Peter Fritz Markus Ketteler Mark Dominik Alscher Moritz Schanz
author_facet	Severin Schricker Tina Oberacker Peter Fritz Markus Ketteler Mark Dominik Alscher Moritz Schanz
author_sort	Severin Schricker
title	Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients
title_short	Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients
title_full	Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients
title_fullStr	Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients
title_full_unstemmed	Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients
title_sort	peritoneal expression of sglt-2, glut1 and glut3 in peritoneal dialysis patients
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/bb15b0e468944e739b7005a8fb2d7b12
work_keys_str_mv	AT severinschricker peritonealexpressionofsglt2glut1andglut3inperitonealdialysispatients AT tinaoberacker peritonealexpressionofsglt2glut1andglut3inperitonealdialysispatients AT peterfritz peritonealexpressionofsglt2glut1andglut3inperitonealdialysispatients AT markusketteler peritonealexpressionofsglt2glut1andglut3inperitonealdialysispatients AT markdominikalscher peritonealexpressionofsglt2glut1andglut3inperitonealdialysispatients AT moritzschanz peritonealexpressionofsglt2glut1andglut3inperitonealdialysispatients
_version_	1718393763554918400

Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients

Ejemplares similares